Mirna Therapeutics (NASDAQ: MIRN) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitabiliy and dividends.

Valuation and Earnings

This table compares Mirna Therapeutics and KalVista Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Mirna Therapeutics N/A N/A -$17.76 million ($1.37) -1.23
KalVista Pharmaceuticals $1.50 million 46.95 -$15.90 million N/A N/A

KalVista Pharmaceuticals has higher revenue and earnings than Mirna Therapeutics.

Risk and Volatility

Mirna Therapeutics has a beta of 3.67, meaning that its share price is 267% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500.

Profitability

This table compares Mirna Therapeutics and KalVista Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mirna Therapeutics N/A -41.99% -39.48%
KalVista Pharmaceuticals -5,863.31% -63.41% -59.01%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Mirna Therapeutics and KalVista Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirna Therapeutics 0 5 0 0 2.00
KalVista Pharmaceuticals 0 0 0 0 N/A

Mirna Therapeutics currently has a consensus target price of $4.10, indicating a potential upside of 144.05%. Given Mirna Therapeutics’ higher possible upside, equities research analysts clearly believe Mirna Therapeutics is more favorable than KalVista Pharmaceuticals.

Institutional & Insider Ownership

37.4% of Mirna Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of KalVista Pharmaceuticals shares are owned by institutional investors. 18.6% of Mirna Therapeutics shares are owned by insiders. Comparatively, 45.3% of KalVista Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Mirna Therapeutics beats KalVista Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Mirna Therapeutics Company Profile

Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company’s RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.